BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Naučno-praktičeskaâ revmatologiâ 2021;59:537-546. [DOI: 10.47360/1995-4484-2021-537-546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: history and modernity. Naučno-praktičeskaâ revmatologiâ 2022;60:397-412. [DOI: 10.47360/1995-4484-2022-397-412] [Reference Citation Analysis]
2 Leineman YA, Bessalova AY, Aliev DB, Samigullina RR, Shostak MS, Gaidukova IZ, Mazurov VI. Experience with type I interferon inhibitor in systemic lupus erythematosus. Sovremennaâ revmatologiâ 2022;16:69-73. [DOI: 10.14412/1996-7012-2022-4-69-73] [Reference Citation Analysis]
3 Nasonov EL, Lila AM, Dubinina TV, Nikininskaya OA, Amirdjanova VN. Advances in rheumatology at the beginning of the 21st century. Naučno-praktičeskaâ revmatologiâ 2022;60:5-20. [DOI: 10.47360/1995-4484-2022-5-20] [Reference Citation Analysis]